Andre is an experienced healthcare executive with a proven track record in creating strategic partnerships, scaling startups, large enterprise sales agreements, business development and product innovation. Andre is an integral part of the digital solution landscape and is also an active member in the global digital health ecosystem. He has previously held leadership positions at both 2nd.MD and DoseMe.

Dr. Manion, VP for Innovation, has held executive positions in biomedical informatics support at two major NCI-designated comprehensive cancer centers. He served as Chief Technology Officer and Deputy CIO at the Fox Chase Cancer Center. Until joining Melax he was the Chief Informatics Officer at the Rogel Cancer Center of the University of Michigan. His research interest are the formal semantic representation of biomedical research and clinical data.

Dr. Zhang serves as the Director of NLP Research in Melax. Before joining Melax, she was an Assistant Professor in The University of Texas Health Science Center at Houston. Her primary research interests include natural language processing (NLP), text mining and machine learning. In the past eight years, she has contributed to multiple top ranked systems in biomedical NLP competitions. Her research also contributed to Pharmacovigilance and genetic information extraction from clinical trials.

A biophysicist by training, Dr. Ding was fascinated by natural language processing, machine learning, and the impact of new technology that will bring to the healthcare industry. Since joining Melax Technologies in 2018, Hao has been passionate about expanding business development and revenue generation, managing company daily operation, and ultimately contributing to the improvement of the healthcare system. When not working hard in front of his computer, Hao enjoys spending time with his family and sweating in the gym.

Dr. Xu is the Founder of Melax Technologies Inc. He received his PhD in Biomedical Informatics from Columbia University, and currently is also a part-time professor at The University of Texas Health Science Center at Houston. In the past decade, he has worked on a broad range of challenging NLP topics and clinical NLP methods and systems developed in his lab have been highly recognized. He served as the Chair of AMIA NLP Working Group and currently also leads the NLP Working Group at OHDSI.